Etomidate Catalog No.:M9467-10 Ambrisentan significantly improved exercise capacity

Ambrisentan significantly improved exercise capacity (6-minute walk distance) compared with placebo in two double-blind

but not shape change induced by sub-maximal concentrations of thrombin

TBB also inhibits three other kinases with less potency: CDK2 (IC50=15

InChi: InChI=1S/C38H37ClN8O7S

It is rapidly absorbed after oral administration

Etomidate Catalog No.:M9467-10 Ambrisentan significantly improved exercise capacityEtomidate is a short acting intravenous anaesthetic agent used for the induction of general anaesthesia and sedation for short procedures such as reduction of dislocated joints, tracheal intubation, and cardioversion. It was discovered at Janssen Pharmaceutica in 1964 and was introduced as an intravenous agent in 1972 in Europe and in 1983 in the United States. Product information CAS Number: 33125 97 2 Molecular Weight: 244. 29 Formula: C14H16N2O2